Abstract
Alopecia areata is a complex immune-mediated disease that targets anagen hair follicles. Therapeutic strategies must be directed as either immunosuppressive or immunomodulating and may consist of monotherapy or combination therapy and should be different depending on patient’s age, extent, and chronicity of the disease. The physician must discuss mild and aggressive options, as well as the possibility of no treatment, camouflage options, and social/psychological support. Topical, intralesional, and systemic steroids, as well as corticosteroid-sparing agents and disease-modifying antirheumatic drugs are useful as local or systemic immunosuppressors. Topical immunotherapy, anthralin, and phototherapy have proved useful as immunomodulators. Target therapy with JAK inhibitors is useful in alopecia areata totalis or universalis. Treatment in special areas such as eyelashes, eyebrows, or beard benefit from treatment with steroids, minoxidil, prostaglandin F2a analogs, and topical tofacitinib. Vitamin D3, ezetimibe/simvastatin, platelet-rich plasma, antihistamines, and aromatherapy may be used as adjuvant therapies. We discuss a practical but evidence-based approach for treatment in different cases of alopecia areata with detailed information about doses, administration, and possible side effects.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Tosti A, Iorizzo M, Botta GL, Milani M. Efficacy and safety of a new clobetasol propionate 0.05% foam in alopecia areata: a randomized, double-blind placebo-controlled trial. J Eur Acad Dermatol Venereol. 2006;20(10):1243–7.
Kubeyinje E. Intralesional triamcinolone acetonide in alopecia areata amongst 62 Saudi Arabs. East Afr Med J. 1994;71(10):674–65.
Melo DF, Dutra TB de S, Baggieri VMAC, Tortelly VD. Intralesional betamethasone as a therapeutic option for alopecia areata. An Bras Dermatol. 2018;93(2):311–2.
Chang KH, Rojhirunsakool S, Goldberg LJ. Treatment of severe alopecia areata with intralesional steroid injections. J Drugs Dermatol. 2009;8(10):909–12.
Gensure RC. Clinical response to combined therapy of cyclosporine and prednisone. J Investig Dermatol Symp Proc. 2013;16(1):S58.
Shaheedi-Dadras M, Karami A, Mollaei F, Mollaei M, Moravvej H, Moravej T, et al. The effect of methylprednisolone pulse-therapy plus oral cyclosporine in the treatment of alopecia totalis and universalis. Arch Iran Med. 2008;11(1):90–3.
Köse O, Safali M, Bulent Tastan H, Gur AR. Mycophenolate mofetil in extensive alopecia areata: no effect in seven patients. Dermatology. 2004;209(1):69–70.
Kanameishi S, Dainichi T, Endo Y, Otsuka A, Tanioka M, Kabashima K. Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis. J Eur Acad Dermatology Venereol. 2017;31(3):e137–8.
Bakar O, Gurbuz O. Is there a role for sulfasalazine in the treatment of alopecia areata? J Am Acad Dermatol. 2007;57(4):703–6.
Rashidi T, Mahd AA. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol. 2008;47(8):850–2.
Alkeraye S, Becquart C, Delaporte E, Staumont-Sallé D. Efficacy of combining pulse corticotherapy and methotrexate in alopecia areata: real-life evaluation. J Dermatol. 2017;44(12):e319–20.
Singh G, Lavanya M. Topical immunotherapy in alopecia areata. Int J Trichol. 2010;2(1):36–9.
Happle R, Klein HM, Macher E. Topical immunotherapy changes the composition of the peribulbar infiltrate in alopecia areata. Arch Dermatol Res. 1986;278(3):214–8.
Fiedler-weiss VC. Evaluation of anthralin in the treatment of alopecia areata. Arch Dermatol. 1987;123:21–3.
Bulat V, Situm M, Dediol I, Ljubicić I, Bradić L. The mechanisms of action of phototherapy in the treatment of the most common dermatoses. Coll Antropol. 2011;35 Suppl 2:147–51.
Ito T. Advances in the management of alopecia areata. J Dermatol. 2012;39(1):11–7.
McMichael AJ. Excimer laser: a module of the alopecia areata common protocol. J Investig Dermatol Symp Proc. 2013;16(1):S77–9.
Zakaria W, Passeron T, Ostovari N, Lacour J-P, Ortonne J-P. 308-nm excimer laser therapy in alopecia areata. J Am Acad Dermatol. 2004;51(5):837–8.
Al-Mutairi N. 308-nm excimer laser for the treatment of alopecia areata in children. Pediatr Dermatol. 2009;26(5):547–50.
Whitmont KJ, Cooper AJ. PUVA treatment of alopecia areata totalis and universalis: a retrospective study. Australas J Dermatol. 2003;44:106–9.
Behrens-Williams SC, Leiter U, Schiener R, Weidmann M, Peter RU, Kerscher M. The PUVA-turban as a new option of applying a dilute psoralen solution selectively to the scalp of patients with alopecia areata. J Am Acad Dermatol. 2001;44(2):248–52.
Herz-Ruelas ME, Gomez-Flores M, Miranda-Maldonado I, Welsh E, Ocampo-Candiani J, Welsh O. Escalating dosimetry of UVA-1 in the treatment of alopecia areata. Int J Dermatol. 2017;56(6):653–9.
França K, Castillo D, Tchernev G, Lotti T. UVA-1 in the treatment of alopecia areata. Dermatol Ther. 2017;30(6):e12547.
Bayramgürler D, Demirsoy EO, Aktürk AŞ, Kıran R. Narrowband ultraviolet B phototherapy for alopecia areata. Photodermatol Photoimmunol Photomed. 2011;27(6):325–7.
Waiz M, Saleh AZ, Hayani R, Jubory SO. Use of the pulsed infrared diode laser (904 nm) in the treatment of alopecia areata. J Cosmet Laser Ther. 2006;8(1):27–30.
Craiglow BG. Topical tofacitinib solution for the treatment of alopecia areata affecting eyelashes. JAAD Case Rep. 2018;4(10):988–9.
Jabbari A, Sansaricq F, Cerise J, Chen JC, Bitterman A, Ulerio G, et al. An open-label pilot study to evaluate the efficacy of tofacitinib in moderate to severe patch-type alopecia areata, totalis, and Universalis. J Invest Dermatol. 2018;138(7):1539–45.
Mackay-Wiggan J, Jabbari A, Nguyen N, Cerise JE, Clark C, Ulerio G, et al. Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata. JCI Insight. 2016;1(15)
Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, et al. Reversal of alopecia areata following treatment with the JAK1/2 inhibitor baricitinib. EBioMedicine. 2015;2(4):351–5.
Liu LY, Craiglow BG, King BA. Tofacitinib 2% ointment, a topical Janus kinase inhibitor, for the treatment of alopecia areata: a pilot study of 10 patients. J Am Acad Dermatol. 2018;78(2):403–404.e1.
Bayart CB, DeNiro KL, Brichta L, Craiglow BG, Sidbury R. Topical Janus kinase inhibitors for the treatment of pediatric alopecia areata. J Am Acad Dermatol. 2017;77(1):167–70.
Renert-Yuval Y, Guttman-Yassky E. A novel therapeutic paradigm for patients with extensive alopecia areata. Expert Opin Biol Ther. 2016;16(8):1005–14.
Zorn E, Mohseni M, Kim H, Porcheray F, Lynch A, Bellucci R, et al. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(3):382–8.
Tsai T-Y, Huang Y-C. Vitamin D deficiency in patients with alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(1):207–9.
Mahamid M, Abu-Elhija O, Samamra M, Mahamid A, Nseir W. Association between vitamin D levels and alopecia areata. Isr Med Assoc J. 2014;16(6):367–70.
Lattouf C, Jimenez JJ, Tosti A, Miteva M, Wikramanayake TC, Hershkovitz I, et al. Treatment of alopecia areata with simvastatin/ezetimibe. J Am Acad Dermatol. 2015;72(2):359–61.
Ballantyne C, Ridker P, Person T. Effects of ezetimibe/simvastatin compared to simvastatin monotherapy in reducing C-reactive protein and low density lipoprotein-cholesterol. J Am Coll Cardiol. 2006;4(suppl A):316A.
Robins DN. Alopecia Universalis: hair growth following initiation of simvastatin and ezetimibe therapy. J Drugs Dermatol. 2007;6(9):946–7.
Thompson JM, Mirza MA, Park MK, Qureshi AA, Cho E. The role of micronutrients in alopecia areata: a review. Am J Clin Dermatol. 2017;18(5):663–79.
Inui S, Nakajima T, Toda N, Itami S. Fexofenadine hydrochloride enhances the efficacy of contact immunotherapy for extensive alopecia areata: retrospective analysis of 121 cases. J Dermatol. 2009;36(6):323–7.
Ohyama M, Shimizu A, Tanaka K, Amagai M. Experimental evaluation of ebastine, a second-generation anti-histamine, as a supportive medication for alopecia areata. J Dermatol Sci. 2010;58(2):154–7.
Hay IC, Jamieson M, Ormerod AD. Randomized trial of aromatherapy. Successful treatment for alopecia areata. Arch Dermatol. 1998;134(11):1349–52.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Vazquez-Herrera, N.E., Tosti, A. (2020). Alopecia Areata: Clinical Treatment. In: Tosti, A., Asz-Sigall, D., Pirmez, R. (eds) Hair and Scalp Treatments. Springer, Cham. https://doi.org/10.1007/978-3-030-21555-2_9
Download citation
DOI: https://doi.org/10.1007/978-3-030-21555-2_9
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-21554-5
Online ISBN: 978-3-030-21555-2
eBook Packages: MedicineMedicine (R0)